Brief: Acrux Ltd And Dash Pharmaceuticals Mutually Terminate Commercialisation Agreement
19/09/2023 02:26
Sept 19 (Reuters) - Acrux Ltd ACR.AX :
* ACRUX AND DASH PHARMACEUTICALS MUTUALLY TERMINATE
COMMERCIALISATION AGREEMENT
* ACRUX RETAINS EXCLUSIVE OWNERSHIP OF ALL RIGHTS AND
INTELLECTUAL
PROPERTY ASSOCIATED WITH GENERIC TESTOSTERONE TOPICAL SOLUTION
PRODUCT
Source text for Eikon: ID:nASX47LPyl
Further company coverage: ACR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acrux
See all newsBrief: Acrux Licenses Lenzetto For Australian Market For A$5.4 Million
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program
Brief: Acrux Raises A$1.6 Mln Via At 0.95 AU Cents Per Share